Who is Inovise?

Inovise Medical, Inc. is pioneering diagnostic medical technology that is shaping cardiac care worldwide. Our international team of experts in the areas of diagnostic cardiology, patient monitoring, biomedical engineering and healthcare dynamics works collaboratively with globally-respected medical luminaries and corporate leaders to deliver new, innovative diagnostic tools providing both clinical and economic value. 

At Inovise Medical, we strive to become the pervasive vital sign for the heart, and for AUDICOR® technology to be used routinely as an evaluator of cardiac function making it the standard of care for economic, non-invasive, actionable cardiac assessment worldwide. 

Our Commitment to Quality

Inovise Medical Inc., along with the management team and all of its employees is committed to:

  • Providing software and technology services that make a difference in health care
  • Maintaining the effectiveness of quality management system
  • Full compliance with applicable national and international standards

Inovise Medical Inc., is ISO 13485 certified company.


Peter Bauer, President and CEO

Prior to leading the company, Peter Bauer was the Vice President of Technology at Inovise Medical and held multiple Director positions in the area of Research and Development at BIOTRONIK for 8 years. Mr. Bauer began his career in the biomedical industry in 1995 after working many years in several research facilities in Europe in the area of solid-state physics, surface science, and nanotechnology. He holds a Ph.D. in Physics from the University of Erlangen-Nuremberg, Germany.

Alan Andresen, Vice President of Engineering

Alan Andresen co-founded Inovise in 1997 and has since served in pivotal roles including: director of algorithms, product platforms, and international marketing development. Prior to Inovise, Andresen worked at Hewlett-Packard's Cardiology Division for over 12 years, holding technical leadership positions on Holter monitoring and 12 Lead ECG Cardiograph developments. He holds a B.S. in Computer Engineering from Iowa State University.

David A. Chazanovitz, Chairman of the Board

Mr. Chazanovitz most recently served as President and CEO of Alveolus, Inc., a leader in the development of non-vascular interventional stent technology. He served as President and CEO of Cambridge Heart, Inc. and President of several divisions of C.R. Bard, Inc. In 1995, Mr. Chazanovitz founded Interventions, a developer of septal repair devices and served as Division President of NMT Medical, Inc. after the merger of the two companies until 2000. He also serves as Chairman of the Board of MassPro, the Massachusetts quality improvement organization.